



Taysha Gene Therapies to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10

November 3, 2021

DALLAS--(BUSINESS WIRE)--Nov. 3, 2021-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the third quarter ended September 30, 2021, and host a corporate update conference call and webcast on Wednesday, November 10, 2021, at 8:00 AM Eastern Time.

Conference Call Details

Wednesday, November 10, at 8:00 AM Eastern Time / 7:00 AM Central Time

Toll Free: 877-407-0792

International: 201-689-8263

Conference ID: 13723855

Webcast: <https://ir.tayshagtx.com/news-events/events-presentations>

An archived version of the webcast will be available on Taysha's website for 30 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team's proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients' lives. More information is available at www.tayshagtx.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211103005348/en/): <https://www.businesswire.com/news/home/20211103005348/en/>

Company Contact:

Kimberly Lee, D.O.

SVP, Corporate Communications and Investor Relations

Taysha Gene Therapies

klee@tayshagtx.com

Media Contact:

Carolyn Hawley

Canale Communications

carolyn.hawley@canalecomm.com

Source: Taysha Gene Therapies, Inc.